Latest Conference Articles

Melhem Solh, MD, discusses how the standard of care for patients with myelodysplastic syndrome and acute myeloid leukemia with the tumor protein 53 gene mutation has changed over the past decade.

According to a long-term analysis of the ZUMA-1 study, the overall survival rate yielded by axicabtagene ciloleucel may support 1- and 2-year event-free survival as a surrogate end point in relapsed/refractory large B-cell lymphoma.

Frontline treatment with axicabtagene ciloleucel demonstrated a high rate of rapid and durable responses in patients with high-risk large B-cell lymphoma in the phase 2 ZUMA-12 study.

Molecular characteristics associated with resistance to CD19-directed chimeric antigen receptor T-cell therapy for pediatric acute lymphoblastic leukemia can hopefully improve patient selection and eligibility for therapy.

Results from a post-hoc exploratory analysis of the TALAPRO-1 study signal that high genomic loss of heterozygosity may be assiciated with enhanced response to talazoparib in patients with metastatic castration-resistant prostate cancer.

Paul G. Richardson, MD, discusses the latest regulatory movement in the multiple myeloma space.

Findings of CheckMate 816 show improved event-free survival and partial complete response and promising overall survival results with the use of neoadjuvant nivolumab in combination with chemotherapy for patients with resectable NSCLC.

Results from the phase 2 CheckMate-848 study show that nivolumab in combination and ipilimumab may be effective for the treatment of advanced or metastatic tumor mutational burden–high solid tumors that were refractory to standard therapies.

According to Tanjina Kader, PhD, 12% of patients in the cohort who developed new, independent primary tumors raised the question of whether using these genetic biomarkers for prediction of recurrence is a good idea.

Preclinical research indicates that anti-mesothelin chimeric antigen receptor T cells may be more effective than gavocabtagene autoleucel in mesothelin-expressing tumors.

Prolonged periods of radiographic and clinical improvement in children and young adults with H3K27M diffuse intrinsic pontine gliomas and spinal diffuse midline gliomas has been shown with GD2-directed chimeric antigen receptor T cells.

The bispecific antibody therapy AMF13 combined with preactivated and expanded natural killer cells showed encouraging activity in patients with heavily pretreated lymphoma.

Four-year follow-up data from the KEYNOTE-042 show promising survival and durable response in patients with non–small cell lung cancer.

Matthew J. Matasar, MD, discusses the ways to improve on the combination of R-CHOP in patients with diffuse large B-Cell lymphoma.

Evidence for on-target activity of temferon has been demonstrated in patients with glioblastoma, according to the phase 1/2a TEM-GBM study.

According to a phase 1/2 study, nivolumab plus PD-L1/IDO peptide vaccine may be effective for the treatment of patients with metastatic melanoma.

During a presentation, Paul G. Richardson, MD, talked about the shift from triplet combination therapies toward quadruplet combinations for the treatment of multiple myeloma.

Adam Cohen, MD, discusses his presentation on updates in BCMA-directed therapies for multiple myeloma, which he gave during the 3rd Summit of the Americas on Immunotherapies for Hematologic Malignancies.

Guenther Koehne, MD, PhD, discusses the exciting presentations going on at the 3rd Summit of the Americas on Immunotherapies for Hematologic Malignancies.

Lower rates of neutropenia and hypokalemia were also observed with maribavir than valganciclovir, ganciclovir, and foscarnet, and a lower proportion of HCT recipients discontinued treatment with maribavir than IAT.

Relatlimab plus nivolumab demonstrated reduction in risk of progression or death and numerically improved overall survival compared to nivolumab alone.

According to Primo Nery Lara, Jr, MD, frontline treatment options for metastatic renal cell carcinoma have been improving rapidly.

In recent years, the field of metastatic urothelial cancer has seen many new immunotherapy agents and targeted therapies that have improved patient outcomes.

Kevin Kalinsky, MD, MS, discussed selective estrogen receptor downregulators being explored for the treatment of breast cancer clinical trials.

Tailored treatment available to patients with HER2-positive metastatic breast cancer based on the presence of active central nervous system disease.

In the phase 3 monarchE clinical trial, long-term follow-up results show that the benefit of abemaciclib plus endocrine therapy continued beyond 2 years.

A team-oriented approach based on guideline-directed therapies should be used by clinicians to address patients experiencing cardiotoxicity as a result of their breast cancer, according Jean-Bernard Durand, MD.

Progress in the treatment of early-stage triple-negative breast cancer includes the now common use of neoadjuvant combinations of immunotherapy with chemotherapy.

Elacestrant demonstrates statistically significant and clinically meaningful improvement in progression-free survival for patients with ER–positive, HER2-negative mBC who previously received CDK4/6 inhibition.

According to real-world research, eribulin may be an effective treatment for patients with metastatic breast cancer who were previously treated with atezolizumab or sacituzumab govitecan.